Summary
Vertex Pharmaceuticals reported strong financial performance for the fiscal year ending December 31, 2023, with net product revenues reaching $9.9 billion, an increase of 11% year-over-year. This growth was primarily driven by the continued strong uptake of its cystic fibrosis (CF) medicine, TRIKAFTA/KAFTRIO, in international markets and label expansions into younger age groups. The company also achieved significant milestones in its pipeline, notably the approval of CASGEVY for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT) in multiple geographies, including the U.S. Vertex is advancing its "serial innovation" strategy, aiming to provide transformative treatments for serious diseases. Key developments include positive Phase 3 data for a new once-daily triple combination therapy for CF (vanzacaftor/tezacaftor/deutivacaftor), with global regulatory filings planned for mid-2024. Additionally, the company is progressing VX-548, a non-opioid pain therapy, with plans for regulatory submission in acute pain by mid-2024 and advancing into pivotal development for diabetic peripheral neuropathy. The company's robust pipeline and strategic focus on expanding its portfolio beyond CF position it for continued growth.
Financial Highlights
50 data points| Revenue | $9.87B |
| Cost of Revenue | $1.26B |
| Gross Profit | $8.61B |
| SG&A Expenses | $1.14B |
| Operating Expenses | $6.04B |
| Operating Income | $3.83B |
| Net Income | $3.62B |
| EPS (Basic) | $14.05 |
| EPS (Diluted) | $13.89 |
| Shares Outstanding (Basic) | 257.70M |
| Shares Outstanding (Diluted) | 260.50M |
Key Highlights
- 1Net product revenues increased by 11% to $9.9 billion in 2023, driven by strong TRIKAFTA/KAFTRIO performance.
- 2CASGEVY, a gene-edited therapy for sickle cell disease and beta-thalassemia, received approvals in the U.S., EU, UK, Saudi Arabia, and Bahrain.
- 3Positive Phase 3 data for a new once-daily triple combination therapy for cystic fibrosis (vanzacaftor/tezacaftor/deutivacaftor) reported, with global regulatory filings anticipated by mid-2024.
- 4VX-548, a non-opioid therapy for acute pain, completed Phase 3 trials with positive results, and a U.S. NDA submission is planned for mid-2024.
- 5VX-548 is also advancing in development for diabetic peripheral neuropathy.
- 6Research and development expenses increased by 25% to $3.2 billion, reflecting investment in advancing pipeline programs.
- 7The company ended the year with a strong cash position of $13.7 billion, indicating financial flexibility for ongoing operations and pipeline development.